How China became the new world leader in clinical trials
用户tYjsroVqR1jw
1个月前
103
10
已完结
1. 系统已在2026-05-13 11:23:16对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
F Murphy
bmj, 2026
bmj.com
… After investing decades and billions of yuan in becoming a scientific superpower, China
is well placed to benefit from the plight of the US medical research sector. But geopolitical
ructions and local idiosyncrasies could complicate this, writes Flynn Murphy … In
September 2025 the National Medical Products Administration, China’s drug regulator,
announced new rules shortening the review period for certain clinical trial applications to 30
days from 60, matching the US Food and Drug Administration’s 30 day review. But this has …
